507 related articles for article (PubMed ID: 34298601)
21. Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages.
Shen Z; Liu X; Fan G; Na J; Liu Q; Lin F; Zhang Z; Zhong L
J Transl Med; 2023 Nov; 21(1):842. PubMed ID: 37993941
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
23. Combining oncolytic virus with FDA approved pharmacological agents for cancer therapy.
Zhang W; Chen CC; Ning J
Expert Opin Biol Ther; 2021 Feb; 21(2):183-189. PubMed ID: 32799567
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
25. Design and application of oncolytic viruses for cancer immunotherapy.
Ylösmäki E; Cerullo V
Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
[TBL] [Abstract][Full Text] [Related]
26. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
27. Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?
Groeneveldt C; van den Ende J; van Montfoort N
Cytokine Growth Factor Rev; 2023 Apr; 70():1-12. PubMed ID: 36732155
[TBL] [Abstract][Full Text] [Related]
28. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
Muscolini M; Tassone E; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic Viruses in Cancer Treatment: A Review.
Lawler SE; Speranza MC; Cho CF; Chiocca EA
JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
[TBL] [Abstract][Full Text] [Related]
30. Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.
Nguyen T; Avci NG; Shin DH; Martinez-Velez N; Jiang H
Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29857493
[TBL] [Abstract][Full Text] [Related]
31. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
Nguyen HM; Bommareddy PK; Silk AW; Saha D
Semin Cancer Biol; 2022 Nov; 86(Pt 3):971-980. PubMed ID: 34033895
[TBL] [Abstract][Full Text] [Related]
32. Current landscape and perspective of oncolytic viruses and their combination therapies.
Su Y; Su C; Qin L
Transl Oncol; 2022 Nov; 25():101530. PubMed ID: 36095879
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.
Samson A; Bentham MJ; Scott K; Nuovo G; Bloy A; Appleton E; Adair RA; Dave R; Peckham-Cooper A; Toogood G; Nagamori S; Coffey M; Vile R; Harrington K; Selby P; Errington-Mais F; Melcher A; Griffin S
Gut; 2018 Mar; 67(3):562-573. PubMed ID: 27902444
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic viruses as therapeutic cancer vaccines.
Bartlett DL; Liu Z; Sathaiah M; Ravindranathan R; Guo Z; He Y; Guo ZS
Mol Cancer; 2013 Sep; 12(1):103. PubMed ID: 24020520
[TBL] [Abstract][Full Text] [Related]
35. Perspectives on immunotherapy via oncolytic viruses.
Reale A; Vitiello A; Conciatori V; Parolin C; Calistri A; Palù G
Infect Agent Cancer; 2019; 14():5. PubMed ID: 30792754
[TBL] [Abstract][Full Text] [Related]
36. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
37. Genetic modification of oncolytic viruses to enhance antitumor immunity.
Davola ME; Vito A; Wei J; El-Sayes N; Workenhe S; Mossman KL
Methods Enzymol; 2020; 635():231-250. PubMed ID: 32122548
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
Sadri M; Najafi A; Rahimi A; Behranvand N; Hossein Kazemi M; Khorramdelazad H; Falak R
Int Immunopharmacol; 2023 Sep; 122():110470. PubMed ID: 37433246
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies.
Jhawar SR; Thandoni A; Bommareddy PK; Hassan S; Kohlhapp FJ; Goyal S; Schenkel JM; Silk AW; Zloza A
Front Oncol; 2017; 7():202. PubMed ID: 28955655
[TBL] [Abstract][Full Text] [Related]
40. Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy.
Fang C; Xiao G; Wang T; Song L; Peng B; Xu B; Zhang K
Research (Wash D C); 2023; 6():0108. PubMed ID: 37040283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
